PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24857619-7	2014	CONCLUSION: Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation.	Ribavirin	33-42	interferon beta 1	Homo sapiens	141-156	
25132867-2	2014	She subsequently completed 72 weeks of natural IFN-beta plus ribavirin therapy without remarkable adverse effects and achieved a sustained viral response, suggesting differences in the pharmacological properties and biological effects of IFN-alpha and IFN-beta.	Ribavirin	61-70	interferon beta 1	Homo sapiens	252-260	
24857619-0	2014	Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. AIM: This study aims to evaluate the efficacy and safety of interferon-beta plus ribavirin therapy in older Japanese patients.	Ribavirin	21-30	interferon beta 1	Homo sapiens	188-203	
24857619-0	2014	Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. AIM: This study aims to evaluate the efficacy and safety of interferon-beta plus ribavirin therapy in older Japanese patients.	Ribavirin	209-218	interferon beta 1	Homo sapiens	0-15	
24857619-7	2014	CONCLUSION: Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation.	Ribavirin	160-169	interferon beta 1	Homo sapiens	12-27	
23745758-3	2014	IFN-beta was administrated twice a day for 2 weeks followed by 24 or 48 weeks of PEG IFN/RBV.	Ribavirin	89-92	interferon beta 1	Homo sapiens	0-8	
22357660-6	2012	Such enhancement depended on autocrine IFN-beta being enhanced by RBV.	Ribavirin	66-69	interferon beta 1	Homo sapiens	39-47	
22357660-9	2012	CONCLUSIONS: Ribavirin augments the anti-HCV effects of IFN-alpha induced by ISGs through enhancing autocrine IFN-beta.	Ribavirin	13-22	interferon beta 1	Homo sapiens	110-118	
20070395-0	2010	Advantage of IFN-beta/alpha2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C. AIM: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia.	Ribavirin	58-67	interferon beta 1	Homo sapiens	13-21	
16060397-0	2005	Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin improves the rate of eradication of the virus by less than 20% in patients with genotype 1b and a high viral load.	Ribavirin	187-196	interferon beta 1	Homo sapiens	0-15	
12719586-11	2003	Because IFN-beta expression itself was reduced in the ribavirin-treated cells, we further investigated the mechanism for up-regulation of the IFN-signaling pathway.	Ribavirin	54-63	interferon beta 1	Homo sapiens	8-16	
11169057-7	2000	CONCLUSIONS: The results of this pilot study indicate that interferon beta-la administered subcutaneously is an effective therapy for some patients with chronic hepatitis C, and suggest that interferon beta-1a deserves further evaluations in larger trials especially in combination with ribavirin.	Ribavirin	287-296	interferon beta 1	Homo sapiens	59-74	
22487191-5	2012	By induction with IFN-beta, even in refractory cases, the high virus negative conversion rate in the early treatment phase and actions of pegylated IFN-alpha-2b and ribavirin in the maintenance treatment phase led to an additive effect.	Ribavirin	165-174	interferon beta 1	Homo sapiens	18-26	
21677781-7	2011	Remarkably, ongoing protein synthesis and viral replication are required to maintain repression of the IFNbeta gene in persistently infected cells, as the gene can be activated by the protein synthesis inhibitor cycloheximide, or by the antiviral drug ribavirin.	Ribavirin	252-261	interferon beta 1	Homo sapiens	103-110	
21161001-10	2010	CONCLUSION: These results suggest the possibilities of shortening the duration of Peg-IFN plus RBV combination therapy by actively reducing HCV-RNA levels using the IFN-beta induction regimen.	Ribavirin	95-98	interferon beta 1	Homo sapiens	165-173	
20428788-7	2010	It was found that IFN beta and/or RBV suppressed miR-122 expression marginally, with a synergetic anti-HCV effect between IFN beta and RBV.	Ribavirin	34-37	interferon beta 1	Homo sapiens	122-130	
17654600-7	2007	In the IFN beta-1a/ribavirin group, 73 of 127 patients (57.5%) achieved an SVR [P < 0.001 versus IFN beta-1a; the adjusted odds ratio was 4.54 (95% confidence interval: 2.53, 8.13)].	Ribavirin	19-28	interferon beta 1	Homo sapiens	7-15	
17654600-7	2007	In the IFN beta-1a/ribavirin group, 73 of 127 patients (57.5%) achieved an SVR [P < 0.001 versus IFN beta-1a; the adjusted odds ratio was 4.54 (95% confidence interval: 2.53, 8.13)].	Ribavirin	19-28	interferon beta 1	Homo sapiens	100-108	
17654600-10	2007	The addition of ribavirin to IFN beta-1a significantly increased the proportion of patients who achieved an SVR versus IFN beta-1a monotherapy.	Ribavirin	16-25	interferon beta 1	Homo sapiens	119-127